Oncology Research International

Oncology Research International is an Australian preclinical biotech focused on discovering and developing plant-derived anticancer therapeutics. The company positions its lead assets as low-cost, immune-oncology-oriented cancer therapies with activity across multiple solid tumor types. ORIL’s lead candidate, ORIL019, has been described by the company as a patented first-in-class program intended to stimulate anticancer immune responses and to be used either alone or in combination with other cancer therapies. The company has also described a broader pipeline including oral and formulation-based programs derived from its plant-based platform. ORIL appears to operate as a public unlisted company and uses a lean, outsourced development model involving external research institutes, universities, hospitals, and CRO partners.